FDA approves overdose drug Narcan as 1st over-the-counter opioid treatment
The Food and Drug Administration on Wednesday approved over-the-counter sales of Narcam, the leading version of the opioid overdose reversal drug naloxone. Narcan is the first opioid treatment to get approval for sale without a prescription, and advocates and the Biden administration hope wider distribution will cut the number of Americans dying from fentanyl, heroin, oxycodone, and other opioid overdoses. Almost two-thirds of the 107,000 U.S. overdose deaths recorded in 2021 were from the synthetic opioid fentanyl.
Addiction and overdose experts said the efficacy of selling Narcan over the counter will depend on how many stores decide to stock it, where and how they display it on shelves, whether insurance plans will cover it, and how much its manufacturer, Emergent BioSolutions, decides to charge for a two-dose nasal spray package. Currently, the two-dose package of Narcan reportedly sells for about $47.
The FDA is likely to approve a second OTC naloxone spray, RiVine, which the nonprofit Harm Reduction Therapeutics sells for about $18 a unit, The Washington Post reports, and generic versions would be even cheaper if approved.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The FDA said, after Emergent studied the issue, that Narcan requires no specialty training to administer. One dose typically revives people overdosing on opioids, though fentanyl overdoses can require several doses. Before administering Narcan, people should call 911 and request an ambulance. Emergent said Narcan should be available on store shelves by late summer.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
6 homes built in the 1700sFeature Featuring a restored Federal-style estate in Virginia and quaint farm in Connecticut
-
Tariffs: Will Trump’s reversal lower prices?Feature Retailers may not pass on the savings from tariff reductions to consumers
-
American antisemitismFeature The world’s oldest hatred is on the rise in U.S. Why?
-
Nitazene is quietly increasing opioid deathsThe explainer The drug is usually consumed accidentally
-
Can TrumpRx really lower drug prices?Today’s Big Question Pfizer’s deal with Trump sent drugmaker stocks higher
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
The UK’s opioid crisis: why the stats don’t add upThe Explainer A new report has revealed that the UK’s total of opioid-related deaths could be much greater than official figures show
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Why the FDA wants to restrict kratom-related productsIn the Spotlight The compound is currently sold across the United States
